Renal cell carcinoma presenting as an ominous metachronous scalp metastasis

Lisa G. Smyth, MD; Rowan G. Casey, MD; David M. Quinlan, MD

Abstract
Renal cell carcinoma (RCC) accounts for 3% of all solid organ tumours and is slightly more common in men in the age range of 60 to 70 years. Skin metastases occur in 3% to 6% of RCCs. There are only approximately 30 cases of scalp metastases secondary to RCC in the literature. They usually occur late in metastatic disease and are a bad prognostic marker. A 67-year-old Caucasian male presented with a metastatic scalp lesion, 10 years post-radical treatment for RCC. His initial diagnosis was a T3bN0M0 RCC. He presented with a raised erythematous lesion on his parietal scalp, the histology of which demonstrated late metastatic recurrence. Shortly after this, he developed diffuse metastatic disease. Metastatic RCC can occur many years after initial diagnosis and present in many forms. Cutaneous metastatic lesions of RCC can mimic many other dermatologic conditions and carries an ominous prognosis. It is therefore important not only for the urologist, but also general practitioners and patients to be vigilant of any new skin lesion as a portent of impending metastatic disease.

Introduction
Renal cell cancer (RCC) accounts for 3% of all solid tumours with an increasing incidence worldwide. There is expected to be a total of 57,760 cases of RCC diagnosed in the United States in 2009 with 12,980 estimated deaths. Despite developments in imaging and treatment of metastatic RCC with immunotherapy (interferon) and vascular endothelial growth factor targeting agents (e.g., sunitinib), the prognosis remains poor with 20% to 50% of patients with localized disease relapsing post-nephrectomy. Up to 30% of patients present with metastases and the median survival for metastatic disease is 10 to 12 months. The most common sites of metastatic RCC recurrence are the lung, lymph nodes, liver and bone. Cutaneous metastases are rare (3% to 6% of cases) and scalp metastases are extremely uncommon. There are approximately 30 cases in the literature.
His case was discussed at a multidisciplinary meeting and it was decided to treat his single brain metastasis (<3 cm right thalamus) with steroids, whole brain and then stereotactic radiotherapy. His renal failure resolved and he was started on sunitinib malate; however, his metastatic disease progressed and he died 9 months later.

Discussion

Renal cell carcinoma recurs in 20% to 40% of patients with clinically localized disease post-nephrectomy and most recurrences occur in the first 3 years. Frequent sites include lung (75%), local lymph nodes (65%), bone (40%), liver (40%), brain (5%) and contra-lateral kidney. Approximately 2% to 10% of patients develop adrenal metastases. The most common tumors to metastasize to the skin are breast, lung and colon cancer and overall the scalp is affected in 6.9% of cases. Scalp metastases are thought to result from hematogenous spread or direct extension of nodal disease and develop there due to the high degree of vascularity and immobility. Cancers of the genito-urinary tract account for 10% of cutaneous metastatic lesions. Renal cell carcinoma is the most common genito-urinary cancer to metastasise to the skin and accounts for 6.8% of cutaneous metastases. They are more commonly found in men. Although it is usually seen at the later stages of the disease, RCC may present initially with a synchronous cutaneous metastasis.

Renal metastatic cutaneous lesions are described as well-circumscribed, cutaneous nodules that are flesh-Coloured, violaceous, blue or appear as a cutaneous horn. They are frequently very vascular and pulsatile. They may mimic other conditions, such as osteomyelitis, septic arthritis, gout, pyogenic granuloma or osteoarthritic disease. Histologically, they may have a similar appearance to the primary lesion; however, they are frequently poorly differentiated. The cells tend to be clear, pale-staining filled with intracytoplasmic lipid and glycogen embedded in a fibrous and highly vascular stroma. Immunochemistry techniques show positivity for epithelial markers, keratin, epithelial membrane antigen, carcinoembryonic antigen and vimentin. The RCC marker antigen, a monoclonal antibody directed against a normal proximal renal tubule antigen, is a relatively specific marker for cutaneous metastases of RCC.

As in this case, patients may present with a long time interval from their curative radical nephrectomy with metastatic disease. Late recurrences are defined as those occurring 10 or more years after the initial diagnosis. The overall late recurrence rate is about 11%. There is a reported case of a patient surviving 45 years before recurrence. Once they present with cutaneous metastases, patients’ survival is poor; in one study the mean survival was only 7 months. In the same group, 90% of patients had a second metastasis in at least one other site. The mean 5-year survival rate of patients with a cutaneous metastasis is 13% to 50% if there is one lesion present and 0% to 8% in patients with multiple lesions.

Cutaneous metastases can be diagnosed on excisional biopsy or by fine needle biopsy. Treatment is usually excision and can be curative if it is solitary or palliative in disseminated metastatic disease. There is one reported case of scalp metastasis responding completely to hypo-fractionated radiotherapy (13 fractions of 375 cGy) in combination with sorafenib in a patient with pulmonary and scalp metastases. Radiotherapy can also be used as a palliative treatment in cutaneous lesions in combination with excision if necessary and, interestingly, there is a report of complete spontaneous regression of a scalp metastases.
Conclusion

As cutaneous metastases are underestimated and underdiagnosed, all patients’ skin should be examined routinely by physicians and patients to rule out evidence of cutaneous lesions. Unfortunately, cutaneous metastases can present many years after apparent curative surgery for RCC and portend an ominous prognosis.

Department of Urology, St. Vincent’s University Hospital, Dublin, Ireland

Competing interests: None declared.

This paper has been peer-reviewed.

References


Correspondence: Dr. Lisa G. Smyth, Conway Institute of Biomolecular & Biomedical Research, University College Dublin, Belfield, Dublin 4, Ireland, fax: +353 1 716 6701; lisa.smyth@ucd.ie